Full Press Release Details
to Present at the LEERINK Partners 6th Annual Global Healthcare
Conference on Thursday, February 16, 2017 at 1:30 p.m. ET in New York
NEW YORK--(BUSINESS WIRE)--February 7, 2017--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS),
a biopharmaceutical company focused on developing immunotherapies based
on gene edited CAR T-cells (UCART), today announced that Dr. Andr
Choulika, Chairman and Chief Executive Officer of Cellectis, will
present at the LEERINK Partners 6th Annual Global Healthcare Conference
on Thursday, February 16, 2017 at 1:30 p.m. Eastern Time at the Lotte
New York Palace Hotel in New York.
To access the live webcast of Cellectis' presentation, please visit http://www.cellectis.com/en/events.
A replay of the webcast will be available on Cellectis' website for 90
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene-edited CAR T-cells (UCART). The company's
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 17 years of expertise
in genome engineering - based on its flagship TALEN products and
meganucleases as well as its pioneering electroporation PulseAgile
technology - to create a new generation of immunotherapies. CAR
technologies are designed to target surface antigens expressed on cells.
Using its life-science-focused, pioneering genome-engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets. Cellectis is listed on
the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market
(ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN is a registered trademark
owned by the Cellectis Group.
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company's
objectives based on the current expectations and assumptions of the
Company's management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.
VP of Communications
Strategic Communications
Caitlin Kasunich, 212-896-1241
Harnest, 646-385-9008
VP of Corporate Strategy and Finance